NMPA introduces newly-revised drug administration law to EU representatives
A conference for publicizing China's newly-revised drug administration law, co-sponsored by the National Medical Products Administration (NMPA), the Delegation of the European Union (EU) to China and the Danish Embassy in China, was held on Dec 11 in Beijing, at which the law was introduced to the EU embassies in China and representatives of foreign-invested enterprises.
Xu Jinghe, Deputy Commissioner of the NMPA, Carsten Damsgaard, Danish Ambassador to China, Tim Harrington, Deputy Head of the EU Delegation and Jakob Cold, Deputy Director General of the Danish Medicines Agency, attended and addressed the conference.
Drug safety is crucial to public health. With the mission of protecting and promoting public health, the NMPA is committed to fully implementing the "four strictest requirements" on drug safety, deepening regulatory reform and innovation, and continuously improving the scientific, law-based, international and modernized level of drug regulation.
On Aug 26, 2019, the 12th session of the Standing Committee of the 13th National People's Congress (NPC) passed the newly revised drug administration law, which is of great importance to public drug safety and development of the medical economy.
At the conference, officials of the NMPA introduced the background and main content of the revision, and details concerning drug development, registration administration and post-market regulation.
Attendees of the conference included officials from the EU and its member countries' agencies in China, as well as representatives of EU pharmaceutical industry associations and enterprises.
The attendees spoke highly of the new revision of the law and praised China's progress in drug regulatory reform and innovation. They said that they believe the implementation of the drug administration law will better promote drug innovation and development, facilitate the access of international high-quality drugs to the Chinese market and push forward the sound growth of pharmaceutical industries. They also put forward some suggestions and recommendations on the implementation of the law.
Responsible officials of the NMPA responded positively to the concerns of the EU representatives.